Perioperative management of antiplatelet therapy

British Journal of Anaesthesia

Volumn 111, Issue SUPPL.1, 2013, Pages

  Oprea, A D ^a   Popescu, W M ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

antiplatelet agents; haemorrhage; perioperative period

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CANGRELOR; CLOPIDOGREL; EPTIFIBATIDE; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PRASUGREL; TICAGRELOR; TICLOPIDINE; TIROFIBAN;

ACUTE CORONARY SYNDROME; ARTICLE; BLEEDING; BLOOD CLOTTING; BRAIN HEMORRHAGE; CARDIOVASCULAR MORTALITY; CAROTID ARTERY INJURY; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG FATALITY; DRUG INDICATION; DRUG SAFETY; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FIBRILLATION; HIGH RISK PATIENT; HUMAN; LOADING DRUG DOSE; LOW DRUG DOSE; MORBIDITY; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; OPERATIVE BLOOD LOSS; PATHOGENESIS; PERIOPERATIVE PERIOD; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SURGICAL RISK; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS; VERTEBRAL ARTERY STENOSIS;

EID: 84890758657     PISSN: 00070912     EISSN: 14716771     Source Type: Journal    
DOI: 10.1093/bja/aet402     Document Type: Article

References (176)

1. TenderaM,WojakowskiW. Role of antiplatelet drugs in the prevention of cardiovascular events. Thromb Res 2003; 110: 355-9
2. World Health Organization. Top 10 causes of death. 2013. Available at http://who.int/mediacentre/factsheets/fs310/en/ (accessed 29 August 2013)
3. Hall R, Mazer CD. Antiplatelet drugs: a review of their pharmacology and management in the perioperative period. Anesth Analg 2011; 112: 292-318
4. Meadows TA, Bhatt DL. Clinical aspects of platelet inhibitors and thrombus formation. Circ Res 2007; 100: 1261-75
5. Anitua E, Andia I, Ardanza B, Nurden P, NurdenAT. Autologous platelets as a source of proteins for healing and tissue regeneration. Thromb Haemost 2004; 91: 4-15
6. Büller HR, Ten Cate T. Coagulation and platelet activation pathways. A review of the key components and the way in which these can be manipulated. Eur Heart J 1995 (Suppl. L); 16: 8-10
7. Kirkby NS, Lundberg MH, ChanMV, et al. Blockade of the purinergic P2Y12 receptor greatly increases the platelet inhibitory actions of nitric oxide. Proc Natl Acad Sci USA 2013; 110: 15782-7
8. Kaplan ZS, Jackson SP. The role of platelets in atherothrombosis. Hematology Am Soc Hematol Educ Program 2011; 2011: 51-61
9. Gawaz M, Langer H, May AE. Platelets in inflammation and atherogenesis. J Clin Invest 2005; 115: 3378-84
10. De Meyer SF, Vanhoorelbeke K, Broos K, Salles II, Deckmyn H. Antiplatelet drugs. Br J Haematol 2008; 142: 515-28
11. Costopoulos C, Niespialowska-Steuden M, Kukreja N, Gorog DA. Novel oral anticoagulants in acute coronary syndrome. Int J Cardiol 2013; 167: 2449-55
12. Roth GJ, Majerus PW. The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein. J Clin Invest 1975; 56: 624-32
13. Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production bylow-dose aspirin in healthy subjects. J Clin Invest 1982; 69: 1366-72
14. Awtry EH, Loscalzo J. Aspirin. Circulation 2000; 101: 1206-18
15. CoxD,MareeAO, DooleyM,ConroyR, ByrneMF, Fitzgerald DJ. Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers. Stroke 2006; 37: 2153-8
16. Bochner F,Williams DB, Morris PM, SiebertDM, LloydJV.Pharmacokinetics of low-dose oral modified release, soluble and intravenous aspirin in man, and effects on platelet function. Eur J Clin Pharmacol 1988; 35: 287-94
17. EikelboomJW, Hirsh J, Spencer FA, Baglin TP,Weitz JI. Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: e89-119S
18. Karha J, RajagopalV, Kottke-Marchant K, Bhatt DL. Lackof effect of enteric coating on aspirin-induced inhibition of platelet aggregation in healthy volunteers. Am Heart J 2006; 151: 976.e7-11
19. Patrono C, Coller B, Dalen JE, et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest 1998; 114: 470-88S
20. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation withwarfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council's General Practice Research Framework. Lancet 1998; 351: 233-41
21. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351: 1755-62
22. Raju N, Sobieraj-Teague M, Hirsh J, O'DonnellM, EikelboomJ. Effect of aspirin on mortality in the primary prevention of cardiovascular disease. Am J Med 2011; 124: 621-9
23. Baigent C, Blackwell L, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849-60
24. USPreventive Services Task Force. Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2009; 150: 396-404
25. Mosca L, Benjamin EJ, Berra K, et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women- 2011 update: a guideline from the American Heart Association. Circulation 2011; 123: 1243-62
26. Lewis HD, DavisJW,Archibald DG, et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. N Engl J Med 1983; 309: 396-403
27. Anderson JL, Adams CD, Antman EM, et al. 2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/ non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013; 61: e179-347
28. O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013; 61: 485-510
29. Leon MB, Baim DS, Popma JJ, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med 1998; 339: 1665-71
30. Brilakis ES, Patel VG, Banerjee S. Medicalmanagement after coronary stent implantation: a review. J Am Med Assoc 2013; 310: 189-98
31. Jolly SS, Pogue J, Haladyn K, et al. Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention: insights fromthe PCI-CUREstudy.Eur Heart J 2009;30: 900-7
32. Mehta SR, Bassand JP, Chrolavicius S, et al. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med 2010; 363: 930-42
33. Mangano DT, Multicenter Study of Perioperative Ischemia Research Group. Aspirin and mortality from coronary bypass surgery. N Engl J Med 2002; 347: 1309-17
34. Goldman S, Copeland J, Moritz T, et al. Improvement in early saphenous vein graft patency after coronary artery bypass surgery with antiplatelet therapy: results of a Veterans Administration Cooperative Study. Circulation 1988; 77: 1324-32
35. Hart RG, Halperin JL, McBride R, Benavente O, Man-Son-Hing M, Kronmal RA. Aspirin for the primary prevention of stroke and other major vascular events: meta-analysis and hypotheses. Arch Neurol 2000; 57: 326-32
36. Antithrombotic Trialists' Collaboration. Collaborative metaanalysis of randomisedtrials of antiplatelet therapyfor prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J 2002; 324: 71-86
37. Brott TG, Halperin JL, Abbara S, et al. 2011 ASA/ACCF/AHA/AANN/ AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS guideline on the management of patients with extracranial carotid and vertebral artery disease: executive summary. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American Stroke Association, American Association of Neuroscience Nurses, American Association of Neurological Surgeons, American College of Radiology, American Society of Neuroradiology, Congress of Neurological Surgeons, Society of Atherosclerosis Imaging and Prevention, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of NeuroInterventional Surgery, Society for Vascular Medicine, and Society for Vascular Surgery. Circulation 2011; 124: 489-532
38. McQuaid KR, Laine L. Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials. Am J Med 2006; 119: 624-38
39. He J, Whelton PK, Vu B, Klag MJ. Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials. J Am Med Assoc 1998; 280: 1930-5
40. Mantz J, Samama CM, Tubach F, et al. Impact of preoperative maintenance or interruption of aspirin on thrombotic and bleeding events afterelectivenon-cardiac surgery: the multicentre, randomized, blinded, placebo-controlled, STRATAGEM trial. Br J Anaesth 2011; 107: 899-910
41. Alghamdi AA, Moussa F, Fremes SE. Does the use of preoperative aspirin increase the risk of bleeding in patients undergoing coronary artery bypass grafting surgery? Systematic review and meta-analysis. J Card Surg 2007; 22: 247-56
42. Campbell CL, Smyth S, Montalescot G, Steinhubl SR. Aspirin dose for the prevention of cardiovascular disease: a systematic review. J Am Med Assoc 2007; 297: 2018-24
43. Deray G, Bagnis C, Brouard R, et al. Clopidogrel activities in patients with renal function impairment. Clin Drug Investig 1998; 16: 319-28
44. Slugg PH, Much DR, Smith WB, Vargas R, Nichola P, Necciari J. Cirrhosis does not affect the pharmacokinetics and pharmacodynamics of clopidogrel. J Clin Pharmacol 2000; 40: 396-401
45. MartinMT, Spinler SA, Nutescu EA.Emerging antiplatelet therapies in percutaneous coronary intervention: a focus on prasugrel. Clin Ther 2011; 33: 425-42
46. Small DS, Wrishko RE, Ernest CS, et al. Prasugrel pharmacokinetics and pharmacodynamics in subjects with moderate renal impairment and end-stage renal disease. J Clin Pharm Ther 2009; 34: 585-94
47. Oprea AD, Popescu WM. ADP-receptor inhibitors in the perioperative period: the good, the bad, and the ugly. J Cardiothorac Vasc Anesth 2013; 27: 779-95
48. Bhatt DL. Prasugrel in clinical practice. N Engl J Med 2009; 361: 940-2
49. Kowalczyk M, Banach M, Mikhailidis DP, Hannam S, Rysz J. Ticagrelor- a new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibitors? Med Sci Monit 2009; 15: MS24-30
50. AndersonSD,ShahNK,YimJ, Epstein BJ. Efficacyandsafetyof ticagrelor: a reversible P2Y12 receptor antagonist. Ann Pharmacother 2010; 44: 524-37
51. Butler K, Teng R. Pharmacokinetics, pharmacodynamics, and safety of ticagrelor in volunteers with severe renal impairment. J Clin Pharmacol 2012; 52: 1388-98
52. Capodanno D, Ferreiro JL, Angiolillo DJ. Antiplatelet therapy: new pharmacological agents and changing paradigms. J Thromb Haemost 2013; 11 (Suppl. 1): 316-29
53. Norgard NB. Cangrelor: a novel P2Y12 receptor antagonist. Expert Opin Investig Drugs 2009; 18: 1219-30
54. Hamm CW, Bassand JP, Agewall S, et al. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011; 32: 2999-3054
55. Douketis JD, Spyropoulos AC, Spencer FA, et al. Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: e326-50S
56. WijnsW, Kolh P, Danchin N, et al. Guidelines on myocardial revascularization. Eur Heart J 2010; 31: 2501-55
57. Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: a report of the AmericanCollege ofCardiology Foundation/AmericanHeart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation 2011; 124: e574-651
58. Rooke TW, HirschAT, Misra S, et al. 2011ACCF/AHA focused update of the guideline for the management of patients with peripheral artery disease (updating the 2005 guideline): a report of the AmericanCollege ofCardiology Foundation/AmericanHeart Association Task Force on Practice Guidelines. Circulation 2011; 124: 2020-45
59. Sacco RL, Diener HC, Yusuf S, et al. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med 2008; 359: 1238-51
60. Wann LS, Curtis AB, January CT, et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): a report of the AmericanCollege ofCardiology Foundation/ AmericanHeart Association Task Force on Practice Guidelines. Circulation 2011; 123: 104-23
61. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502
62. Sabatine MS, Cannon CP, Gibson CM, et al. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevationmyocardial infarction treatedwith fibrinolytics: the PCI-CLARITY study. J Am Med Assoc 2005; 294: 1224-32
63. Steinhubl SR, Berger PB, Mann JT, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. J Am Med Assoc 2002; 288: 2411-20
64. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001; 358: 527-33
65. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-15
66. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045-57
67. Morrow DA,Wiviott SD, White HD, et al. Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38: an application of the classification system from the universal definition of myocardial infarction. Circulation 2009; 119: 2758-64
68. Murphy SA, Antman EM, Wiviott SD, et al. Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial. Eur Heart J 2008; 29: 2473-9
69. Cannon CP, Harrington RA, James S, et al. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet 2010; 375: 283-93
70. Harrington RA, Stone GW, McNulty S, et al. Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med 2009; 361: 2318-29
71. Bhatt DL, Lincoff AM, Gibson CM, et al. Intravenous platelet blockade with cangrelor during PCI. N Engl J Med 2009; 361: 2330-41
72. White HD, Chew DP, Dauerman HL, et al. Reduced immediate ischemic events with cangrelor in PCI: a pooled analysis of the CHAMPION trials using the universal definition of myocardial infarction. Am Heart J 2012; 163: 182-90.e4
73. Bhatt DL, Topol EJ. Scientific and therapeutic advances in antiplatelet therapy. Nat Rev Drug Discov 2003; 2: 15-28
74. Navarese EP, Verdoia M, Schaffer A, et al. Ischaemic and bleeding complications with new, compared to standard, ADP-antagonist regimens in acute coronary syndromes: a meta-analysis of randomized trials. QJM 2011; 104: 561-9
75. Pickard AS, Becker RC, Schumock GT, Frye CB. Clopidogrelassociated bleeding and related complications in patients undergoing coronaryartery bypass grafting. Pharmacotherapy 2008;28: 376-92
76. HochholzerW, Wiviott SD, AntmanEM, et al. Predictors of bleeding and time dependence of association of bleeding with mortality: insights fromthe Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38 (TRITON-TIMI 38). Circulation 2011; 123: 2681-9
77. Goodnough LT, Smith PK, Levy JH, et al. Transfusion outcomes in patients undergoing coronary artery bypass grafting treated with prasugrel or clopidogrel: TRITON-TIMI 38 retrospective data analysis. J Thorac Cardiovasc Surg 2013; 145: 1077-82.e4
78. Cayla G, Cuisset T, Silvain J, et al. Prasugrel monitoring and bleeding in real world patients. Am J Cardiol 2013; 111: 38-44
79. Serebruany VL, Dinicolantonio JJ, Can MM, Pershukov IV, Kuliczkowski W. Gastrointestinal adverse events after dual antiplatelet therapy: clopidogrel is safer than ticagrelor, but prasugrel data are lacking or inconclusive. Cardiology 2013; 126: 35-40
80. Bhatt DL, StoneGW,MahaffeyKW, et al. Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med 2013; 368: 1303-13
81. Truong KM, Amankwa K, Kucukarslan S. Platelet glycoprotein IIb/ IIIa-receptor inhibitors in patients with acute coronary syndromes or undergoing percutaneous coronary interventions: a review. Clin Ther 2001; 23: 1145-65
82. Coller BS. Anti-GPIIb/IIIa drugs: current strategies and future directions. Thromb Haemost 2001; 86: 427-43
83. KohlDW, Slavik KJ,Kamath G, Lehr JM, McDonald MJ, Rubio F. Highdose abciximab during coronary angioplasty in a patient with essential thrombocytosis. J Invasive Cardiol 1998; 10: 173-6
84. Mascelli MA, Lance ET, Damaraju L, Wagner CL, Weisman HF, Jordan RE. Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade. Circulation 1998; 97: 1680-8
85. Kereiakes DJ, Broderick TM, Roth EM, et al. Time course, magnitude, andconsistencyof platelet inhibitionbyabciximab, tirofiban, or eptifibatide in patients with unstable angina pectoris undergoing percutaneous coronary intervention. Am J Cardiol 1999; 84: 391-5
86. Vickers S, TheoharidesAD, Arison B, et al. Invitroandin vivostudies on the metabolism of tirofiban. Drug Metab Dispos 1999; 27: 1360-6
87. SchneiderDJ. Anti-platelet therapy: glycoprotein IIb-IIIaantagonists. Br J Clin Pharmacol 2011; 72: 672-82
88. Arora RR, Rai F. Antiplatelet intervention in acute coronary syndrome. Am J Ther 2009; 16: e29-40
89. Sabatine MS, Jang IK. The use of glycoprotein IIb/IIIa inhibitors in patients with coronary artery disease. Am J Med 2000; 109: 224-37
90. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. The PURSUIT Trial Investigators. Platelet glycoprotein IIb/IIIainunstable angina: receptor suppression using integrilin therapy. N Engl J Med 1998; 339: 436-43
91. MemonMA, Blankenship JC,Wood GC, Frey CM, Menapace FJ. Incidence of intracranial hemorrhage complicating treatment with glycoprotein IIb/IIIa receptor inhibitors: a pooled analysis of major clinical trials. Am J Med 2000; 109: 213-7
92. Angiolillo DJ, Sabaté M, Fernández-Ortiz A, Macaya C. Acute stent thrombosis after early withdrawal of platelet glycoprotein IIb/IIIa antagonists: potential rebound prothrombotic effect? Catheter Cardiovasc Interv 2003; 58: 481-4
93. Diehl P, Halscheid C, Olivier C, Helbing T, Bode C, Moser M. Discontinuation of long term clopidogrel therapy induces platelet rebound hyperaggregability between 2 and 6 weeks post cessation. Clin Res Cardiol 2011; 100: 765-71
94. Benzon HT, McCarthy RJ, Benzon HA, et al. Determination of residual antiplatelet activity of clopidogrel before neuraxial injections. Br J Anaesth 2011; 107: 966-71
95. Biondi-Zoccai GG, Lotrionte M, Agostoni P, et al. A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease. Eur Heart J 2006; 27: 2667-74
96. de Souza DG, Baum VC, Ballert NM. Late thrombosis of a drug-eluting stent presenting in the perioperative period. Anesthesiology 2007; 106: 1057-9
97. Artang R, Dieter RS. Analysis of 36 reported cases of late thrombosis in drug-eluting stents placed in coronary arteries. Am J Cardiol 2007; 99: 1039-43
98. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet 2000; 355: 1295-302
99. Di Minno MN, Milone M, Mastronardi P, et al. Perioperative handling of antiplatelet drugs. A critical appraisal. Curr Drug Targets 2013; 14: 880-8
100. Nuttall GA, Horlocker TT, Santrach PJ, Oliver WC, Dekutoski MB, Bryant S. Predictors of blood transfusions in spinal instrumentation and fusion surgery. Spine (Phila Pa 1976) 2000; 25: 596-601
101. Manning BJ, O'Brien N, Aravindan S, Cahill RA, McGreal G, Redmond HP. The effect of aspirin on blood loss and transfusion requirements in patients with femoral neck fractures. Injury 2004; 35: 121-4
102. Chassot PG, Marcucci C, Delabays A, Spahn DR. Perioperative antiplatelet therapy. Am Fam Physician 2010; 82: 1484-9
103. Neilipovitz DT, Bryson GL, Nichol G. The effect of perioperative aspirin therapy in peripheral vascular surgery: a decision analysis. Anesth Analg 2001; 93: 573-80
104. Oscarsson A, Gupta A, Fredrikson M, et al. To continue or discontinue aspirin in the perioperative period: a randomized, controlled clinical trial. Br J Anaesth 2010; 104: 305-12
105. Antolovic D, RakowA, Contin P, et al.Arandomised controlled pilot trial to evaluateandoptimize the use of anti-platelet agents in the perioperative management in patients undergoing general and abdominal surgery-the APAP trial (ISRCTN45810007). Langenbecks Arch Surg 2012; 397: 297-306
106. Ghaffarinejad MH, Fazelifar AF, Shirvani SM, et al. The effect of preoperative aspirin use on postoperative bleeding and perioperative myocardial infarction in patients undergoing coronary artery bypass surgery. Cardiol J 2007; 14: 453-7
107. Thurston AV, Briant SL. Aspirin and post-prostatectomy haemorrhage. Br J Urol 1993; 71: 574-6
108. Korinth MC. Low-dose aspirin before intracranial surgery-results of a survey among neurosurgeons in Germany. Acta Neurochir (Wien) 2006; 148: 1189-96
109. Burger W, Chemnitius JM, Kneissl GD, Rücker G. Low-dose aspirin for secondary cardiovascular prevention-cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation-review and meta-analysis. J Intern Med 2005; 257: 399-414
110. Korte W, Cattaneo M, Chassot PG, et al. Peri-operative management of antiplatelet therapy in patients with coronary artery disease: joint position paper by members of the working group on Perioperative Haemostasis of the Society on Thrombosis and Haemostasis Research (GTH), the working group on Perioperative Coagulation of the Austrian Society forAnesthesiology, Resuscitation and Intensive Care (ÖGARI) and the Working Group Thrombosis of the European Society for Cardiology (ESC). Thromb Haemost 2011; 105: 743-9
111. Popescu WM. Perioperative management of the patient with a coronary stent. Curr Opin Anaesthesiol 2010; 23: 109-15 Perioperative management of antiplatelet therapy BJA
112. Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. J Am Med Assoc 2005; 293: 2126-30
113. Ong AT, McFadden EP, Regar E, de Jaegere PP, van Domburg RT, Serruys PW. Late angiographic stent thrombosis (LAST) events with drug-eluting stents. J Am Coll Cardiol 2005; 45: 2088-92
114. Priebe HJ. Triggers of perioperativemyocardial ischaemia and infarction. Br J Anaesth 2004; 93: 9-20
115. PriebeHJ.Perioperativemyocardial infarction-aetiologyandprevention. Br J Anaesth 2005; 95: 3-19
116. Sharma AK, Ajani AE, Hamwi SM, et al. Major noncardiac surgery following coronary stenting: when is it safe to operate? Catheter Cardiovasc Interv 2004; 63: 141-5
117. Di Minno MN, Prisco D, Ruocco AL, Mastronardi P, Massa S, Di Minno G. Perioperative handling of patients on antiplatelet therapy with need for surgery. Intern Emerg Med 2009; 4: 279-88
118. Sambu N, Warner T, Curzen N. Clopidogrel withdrawal: is there a 'rebound' phenomenon? Thromb Haemost 2011; 105: 211-20
119. Fleisher LA, Beckman JA, Brown KA, et al. ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery) Developed in Collaboration with the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society forVascular MedicineandBiology,andSociety forVascular Surgery. J Am Coll Cardiol 2007; 50: 1707-32
120. Pfisterer M, Nietlispach F, Jeger R, Kaiser C, BASKET Investigators. Drug-eluting coronary stents in clinical practice: lessons from the 'BAsel Stent Kosten-Effektivitäts Trials' (BASKET). A review of the BASKET trials. Swiss Med Wkly 2011; 141: w13263
121. Eisenstein EL,AnstromKJ,KongDF, et al. Clopidogrel useandlongterm clinical outcomes after drug-eluting stent implantation. J Am Med Assoc 2007; 297: 159-68
122. Park SJ, Park DW, Kim YH, et al. Duration of dual antiplatelet therapy after implantation of drug-eluting stents. N Engl J Med 2010; 362: 1374-82
123. GwonHC,HahnJY, ParkKW, et al. Six-monthversus12-monthdual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/PromusVersus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study. Circulation 2012; 125: 505-13
124. Valgimigli M, Campo G, Monti M, et al. Short-versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial. Circulation 2012; 125: 2015-26
125. KimBK,HongMK, Shin DH, et al.Anewstrategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation). J Am Coll Cardiol 2012; 60: 1340-8
126. Wada T, Nakahama M, Toda H, et al. Dual antiplatelet therapy can be discontinued at three months after implantation of zotarolimus-eluting stent in patients with coronary artery disease. ISRN Cardiol 2013; 2013: 518968
127. BrotmanDJ,BakhruM,SaberW, et al. Discontinuation of antiplatelet therapy prior to low-risk noncardiac surgery in patients with drug-eluting stents: a retrospective cohort study. J Hosp Med 2007; 2: 378-84
128. Wijeysundera DN, Wijeysundera HC, Yun L, et al. Risk of elective major noncardiac surgery after coronary stent insertion: a population-based study. Circulation 2012; 126: 1355-62
129. Dimitrova G, Tulman DB, Bergese SD. Perioperative management of antiplatelet therapy in patients with drug-eluting stents. HSR Proc Intensive Care Cardiovasc Anesth 2012; 4: 153-67
130. Grines CL, BonowRO, Casey DE, et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular AngiographyandInterventions, AmericanCollege of Surgeons, and American Dental Association, with representation from the American College of Physicians. J Am Dent Assoc 2007; 138: 652-5
131. Anderson MA, Ben-Menachem T, Gan SI, et al. Management of antithrombotic agents for endoscopic procedures. Gastrointest Endosc 2009; 70: 1060-70
132. Lillis T, ZiakasA, Koskinas K, Tsirlis A, GiannoglouG. Safety of dental extractions during uninterrupted single or dual antiplatelet treatment. Am J Cardiol 2011; 108: 964-7
133. Abdel Samie A, Theilmann L. Endoscopic procedures in patients under clopidogrel/dual antiplatelet therapy: to do or not to do? J Gastrointestin Liver Dis 2013; 22: 33-6
134. Abdel Samie A, Stumpf M, Sun R, Theilmann L. Biliary-pancreatic endoscopic and surgical procedures in patients under dual antiplatelet therapy: a single-center study. Clin Endosc 2013; 46: 395-8
135. Mason JO, Gupta SR, Compton CJ, et al. Comparison of hemorrhagic complications of warfarin and clopidogrel bisulfate in 25-gauge vitrectomy versus a control group. Ophthalmology 2011; 118: 543-7
136. Cook-Norris RH, Michaels JD,Weaver AL, et al. Complications of cutaneous surgery in patients taking clopidogrel-containing anticoagulation. J Am Acad Dermatol 2011; 65: 584-91
137. Saadeh C, Sfeir J. Discontinuation of preoperative clopidogrel is unnecessary in peripheral arterial surgery. J Vasc Surg 2013 Advance Access published on 24 July 2013, doi: 10.1016/ j.jvs.2013.05.092
138. Chechik O, Goldstein Y, Behrbalk E, Kaufman E, Rabinovich Y. Blood loss and complications following carotid endarterectomy in patients treated with clopidogrel. Vascular 2012; 20: 193-7
139. Stone DH, Goodney PP, Schanzer A, et al. Clopidogrel is not associated with major bleeding complications during peripheral arterial surgery. J Vasc Surg 2011; 54: 779-84
140. Cerfolio RJ, Minnich DJ, Bryant AS. General thoracic surgery is safe in patients taking clopidogrel (Plavix). J Thorac Cardiovasc Surg 2010; 140: 970-6
141. Voltolini L, Rapicetta C, Luzzi L, et al. Lung resection for non-small cell lung cancer after prophylactic coronary angioplasty and stenting: short-and long-term results. Minerva Chir 2012; 67: 77-85
142. Sonobe M, Sato T, Chen F, et al. Management of patients with coronary stents in elective thoracic surgery. Gen Thorac Cardiovasc Surg 2011; 59: 477-82
143. Ceppa DP,Welsby IJ,Wang TY, et al. Perioperativemanagement of patients on clopidogrel (Plavix) undergoing major lung resection. Ann Thorac Surg 2011; 92: 1971-6
144. Paul S, Stock C, Chiu YL, et al. Management and outcomes of patients on preoperative Plavix (clopidogrel) undergoing general thoracic surgery. Thorac Cardiovasc Surg 2012; 61: 489-95
145. Chechik O, Thein R, Fichman G, Haim A, Tov TB, Steinberg EL. The effect of clopidogrel and aspirin on blood loss in hip fracture surgery. Injury 2011; 42: 1277-82
146. Nandi S, Aghazadeh M, Talmo C, Robbins C, Bono J. Perioperative clopidogrel and postoperative events after hip and knee arthroplasties. Clin Orthop Relat Res 2012; 470: 1436-41
147. Collinge CA, Kelly KC, Little B,Weaver T, Schuster RD. The effects of clopidogrel (Plavix) and other oral anticoagulants on early hip fracture surgery. J Orthop Trauma 2012; 26: 568-73
148. Feely MA, Mabry TM, Lohse CM, Sems SA, Mauck KF. Safety of clopidogrel in hip fracture surgery. Mayo Clin Proc 2013; 88: 149-56
149. Toepfer NJ, Baylor K, Henry Y, Simmons J, Berger PB. The effect of antiplatelet and anticoagulant therapy on the clinical outcome of patients undergoing ureteroscopy. Urology 2013; 82: 773-9
150. Eberli D, Chassot PG, Sulser T, et al. Urological surgery and antiplatelet drugs after cardiac and cerebrovascular accidents. J Urol 2010; 183: 2128-36
151. Descazeaud A, Robert G, Lebdai S, et al. Impact of oral anticoagulation on morbidity of transurethral resection of the prostate. World J Urol 2011; 29: 211-6
152. Mukerji G, Munasinghe I, Raza A. A survey of the peri-operative management of urological patients on clopidogrel. Ann R Coll Surg Engl 2009; 91: 313-20
153. Illuminati G, Ceccanei G, Pacilè AM, Pizzardi G, Palumbo P, Vietri F. Dual antiplatelet treatment in patients candidates for abdominal surgery. Ann Ital Chir 2014; 83: 291-4
154. O'Riordan JM, Margey RJ, Blake G, O'Connell PR. Antiplatelet agents in the perioperative period. Arch Surg 2009; 144: 69-76
155. Hillis LD, Smith PK, Anderson JL, et al. 2011ACCF/AHAguideline for coronaryartery bypass graft surgery: executivesummary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011; 124: 2610-42
156. Taylor G, Osinski D, Thevenin A, Devys JM. Is platelet transfusion efficient to restore platelet reactivity in patientswhoare responders to aspirin and/or clopidogrel before emergency surgery? J Trauma Acute Care Surg 2013; 74: 1367-9
157. Darvish-Kazem S, Gandhi M, Marcucci M, Douketis JD. Perioperativemanagement of antiplatelet therapy in patients with a coronary stent who need non-cardiac surgery: a systematic review of clinical practice guidelines. Chest 2013 Advance Access published on 8 August 2013, doi: 10.1378/chest.13-0459
158. Cardiac Society of Australia and New Zealand. Guidelines for the management of antiplatelet therapy in patients with coronary stents undergoing non-cardiac surgery. Heart Lung Circ 2010; 19: 2-10
159. Ferraris VA, Saha SP, Oestreich JH, et al. 2012 update to the Society of Thoracic Surgeons guideline on use of antiplatelet drugs in patients having cardiac and noncardiac operations. Ann Thorac Surg 2012; 94: 1761-81
160. Chou S, Eshaghian S, Lamer A, Tran H, Dohad S, Kaul S. Bridging therapy in the perioperative management of patients with drug-eluting stents. Rev Cardiovasc Med 2009; 10: 209-18
161. Rassi AN, Blackstone E, Militello MA, et al. Safety of 'bridging' with eptifibatide for patients with coronary stents before cardiac and non-cardiac surgery. Am J Cardiol 2012; 110: 485-90
162. Pickett AM, Taylor DA, Ackman ML. Prolonged infusion of eptifibatide as bridge therapy between bare-metal stent insertion and cardiovascular surgery: case report and review of the literature. Pharmacotherapy 2010; 30: 127-33e
163. Lizza BD, Kauflin MJ. Extended-infusion eptifibatide to prevent stent thrombosis in a patient undergoing orthopedic surgery. Ann Pharmacother 2011; 45: e28
164. Marcos EG, Da Fonseca AC, Hofma SH. Bridging therapy for early surgery in patients on dual antiplatelet therapy after drug-eluting stent implantation. Neth Heart J 2011; 19: 412-7
165. Savonitto S, D'Urbano M, Caracciolo M, et al. Urgent surgery in patients with a recently implanted coronary drug-eluting stent: a phase II study of 'bridging' antiplatelet therapy with tirofiban during temporary withdrawal of clopidogrel. Br J Anaesth 2010; 104: 285-91
166. Alshawabkeh LI, Prasad A, Lenkovsky F, et al. Outcomes of a preoperative 'bridging' strategy with glycoprotein IIb/IIIa inhibitors to prevent perioperative stent thrombosis in patients with drug-eluting stents who undergo surgery necessitating interruption of thienopyridine administration. EuroIntervention 2013; 9: 204-11
167. Huang PH, Croce KJ, Bhatt DL, Resnic FS. Recommendations for management of antiplatelet therapy in patients undergoing elective noncardiac surgery after coronary stent implantation. Crit Pathw Cardiol 2012; 11: 177-85
168. Ben Morrison T, Horst BM, Brown MJ, Bell MR, Daniels PR. Bridging with glycoprotein IIb/IIIa inhibitors for periprocedural management of antiplatelet therapy in patients with drug eluting stents. Catheter Cardiovasc Interv 2012; 79: 575-82
169. Angiolillo DJ, Firstenberg MS, Price MJ, et al. Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial. J Am Med Assoc 2012; 307: 265-74
170. Cheng DK, Jackevicius CA, Seidelin P, Feindel C, Rouleau JL. Safety of glycoprotein IIb/IIIa inhibitors in urgent or emergency coronary artery bypass graft surgery. Can J Cardiol 2004; 20: 223-8
171. Dyke CM, Jennings LK, Maier G, Andreou C, Daly R, Tamberella MR. Preoperative platelet inhibition with eptifibatide during coronary artery bypass grafting with cardiopulmonary bypass. J Cardiovasc Pharmacol Ther 2007; 12: 54-60
172. Horlocker TT,Wedel DJ, Rowlingson JC, et al. Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (Third Edition). Reg Anesth Pain Med 2010; 35: 64-101
173. GogartenW, Vandermeulen E, Van Aken H, et al. Regional anaesthesia and antithrombotic agents: recommendations of the European Society of Anaesthesiology. Eur J Anaesthesiol 2010; 27: 999-1015
174. Sisk J, Palma M, Cooper C, Eltahawy E, Atallah J. Use of eptifibatide as a bridge antiplatelet agent for intrathecal drug delivery system placement. Pain Physician 2012; 15: 479-83
175. Bauer ME, Bauer ST, Rabbani AB, Mhyre JM. Peripartum management of dual antiplatelet therapy and neuraxial labor analgesia after bare metal stent insertion for acute myocardial infarction. Anesth Analg 2012; 115: 613-5
176. Popescu WM, Gusberg RJ, Barash PG. Epidural catheters and drug-eluting stents: a challenging relationship. J Cardiothorac Vasc Anesth 2007; 21: 701-3